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A growing line of evidence indicates a dysfunctional ubiquitin-proteasome system (UPS)
in cardiac diseases. Anti-hypertrophic effects and improved cardiac function have been
reported after treatment with proteasome inhibitors in experimental models of cardiac
hypertrophy. Here we tested whether proteasome inhibition could also reverse the
disease phenotype in a genetically-modified mouse model of hypertrophic cardiomyopathy
(HCM), which carries a mutation in Mybpc3, encoding the myofilament protein cardiac
myosin-binding protein C. At 7 weeks of age, homozygous mutant mice (KI) have 39%
higher left ventricular mass-to-body-weight ratio and 29% lower fractional area shortening
(FAS) than wild-type (WT) mice. Both groups were treated with epoxomicin (0.5mg/kg/day)
or vehicle for 1 week via osmotic minipumps. Epoxomicin inhibited the chymotrypsin-
like activity by ∼50% in both groups. All parameters of cardiac hypertrophy (including
the fetal gene program) were not affected by epoxomicin treatment in both groups.
In contrast, FAS was 12% and 35% higher in epoxomicin-treated than vehicle-treated
WT and KI mice, respectively. To identify which genes or pathways could be involved
in this positive effect, we performed a transcriptome analysis in KI and WT neonatal
cardiac myocytes, treated or not with the proteasome inhibitor MG132 (1μM, 24h). This
revealed 103 genes (four-fold difference; 5% FDR) which are commonly regulated in both
KI and WT cardiac myocytes. Thus, even in genetically-modified mice with manifest HCM,
proteasome inhibition showed beneficial effects, at least with regard to cardiac function.
Targeting the UPS in cardiac diseases remains therefore a therapeutic option.
Keywords: cardiomyopathy, hypertrophic, Mybpc3, transgenic mice, ubiquitin-proteasome system, proteasome
inhibitors
INTRODUCTION
Along with the autophagy-lysosome pathway, the ubiquitin-
proteasome system (UPS) represents the major proteolytic system
of eukaryotic cells and degrades highly selectively intracellular
cytosolic, nuclear and myofibrillar proteins. A main function
of the UPS is to prevent accumulation of damaged, misfolded
and mutant proteins, but it is also involved in a variety of
biological processes such as cell proliferation, adaptation to
stress and cell death (Zolk et al., 2006). The ATP-dependent
proteolytic process involves polyubiquitination of the target
protein through a series of enzymatic reactions and the sub-
sequent degradation of the polyubiquitinated protein by the
26S proteasome (Mearini et al., 2008). The eukaryotic 26S
proteasome itself is composed of the 19S regulatory parti-
cle, which recognizes, deubiquitinates and unfolds the target
protein, and the 20S core, which degrades the target protein
through three distinct proteolytic activities (chymotrypsin-like,
trypsin-like, and caspase-like). These proteolytic activities can
be inhibited either reversibly by peptide aldehydes and pep-
tide boronates (e.g., bortezomib) or irreversibly by β-lactones
(e.g., PS-519) and epoxyketones (e.g., epoxomicin; Kisselev et al.,
2012).
Alterations of the UPS have been reported in several human
and experimental cardiac diseases. Specifically, accumulation
of polyubiquitinated proteins was a common feature of car-
diac disorders (Kostin et al., 2003; Weekes et al., 2003; Birks
et al., 2008), whereas activities of the proteasome decreased or
increased depending on the status of the cardiac disease (Depre
et al., 2006; Tsukamoto et al., 2006; Birks et al., 2008; Predmore
et al., 2010; Schlossarek et al., 2012a). In the case of an acti-
vated UPS, partial and short-term proteasome inhibition has
shown beneficial effects in different animal models. Treatment
of mice with the irreversible proteasome inhibitor epoxomicin
prevented both left ventricular hypertrophy (LVH) and the asso-
ciated higher proteasome activity induced by short-term trans-
verse aortic constriction (TAC; Depre et al., 2006). Similarly, low
doses of the reversible proteasome inhibitor bortezomib sup-
pressed cardiac hypertrophy in Dahl salt-sensitive rats (Meiners
et al., 2008). In addition to its hypertrophy-preventing effect,
proteasome inhibition has been shown to be even capable to
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reverse preexisting hypertrophy. Administration of epoxomicin at
a stage of pronounced cardiac hypertrophy led to a stabilization
of contractile parameters and a regression of preexisting hyper-
trophy in mice (Hedhli et al., 2008). Likewise, the irreversible
proteasome inhibitor PS-519 attenuated isoprenaline-induced
hypertrophy in mice (Stansfield et al., 2008). In the present
study, we therefore aimed at evaluating whether epoxomicin may
reduce cardiac hypertrophy and improve cardiac function in a
genetically-engineered mouse model of hypertrophic cardiomy-
opathy (HCM), which carries a mutation in Mybpc3, encoding
the myofilament protein cardiac myosin-binding protein C. The
corresponding human c.772G>A MYBPC3 mutation is one of
the most frequent HCM mutations (found in 13% unrelated
HCM patients; Olivotto et al., 2008) and associated with a bad
prognosis (Richard et al., 2003). Homozygous KI mice develop
systolic dysfunction after postnatal day 1 and LVH at postnatal
day 3 (Gedicke-Hornung et al., 2013; Mearini et al., 2013). The
present study was performed at the age of 7 weeks, an age at
which KI mice have been shown to exhibit higher activities of the
proteasome than WT littermates (Schlossarek et al., 2012a).
MATERIALS AND METHODS
ANIMALS
Mice were housed in a controlled animal facility with free access
to water and standard animal chow. The experimental procedures
were in accordance with the German Law for the Protection of
Animals and have been approved by the Authority for Health and
Consumer Protection of the City State of Hamburg, Germany
(Nr. 07/13). Development and initial characterization of the KI
mice was previously reported (Vignier et al., 2009). Both KI and
WT mice were maintained on a Black Swiss background.
ADMINISTRATION OF EPOXOMICIN
Administration of epoxomicin (Enzo Life Sciences) was deliv-
ered to mice by subcutaneously implanted osmotic minipumps
(Alzet, model 1007D) with a dose of 0.5mg/kg/day for 1 week.
Epoxomicin was diluted in NaCl (with 10% DMSO), control
pumps delivered vehicle alone. After filling, the pumps were incu-
bated in saline at 37◦C overnight to achieve the full pumping rate
from the beginning. Animals were anesthetized with isoflurane
(1.5%, Abbott Inc.) for minipump implantation. No decrease
in body weight, no complications and/or side effects related to
treatment with epoxomicin were observed.
ECHOCARDIOGRAPHY
Transthoracic echocardiography was performed before
minipump implantation and after 1-week treatment using
the Vevo 2100 System (VisualSonics, Toronto, Canada). Animals
were anesthetized with isoflurane (1–2%, Abbott Inc.) and fixed
to a warming platform in a supine position. Anesthetic depth was
monitored by electrocardiogram and respiration rate. B-mode
images were obtained using a MS 400 transducer with a frame
rate of 230–400 frames/s. Two-dimensional short axis views were
recorded at the mid-papillary muscle level. The dimensions of the
left ventricle were measured in a short axis view in diastole and
systole. All images were recorded digitally and off-line analysis
was performed using the Vevo 2100 software.
DETERMINATION OF THE CHYMOTRYPSIN-LIKE ACTIVITY
The chymotrypsin-like activity of the proteasome was assessed in
ventricular cytosolic lysates as described previously (Schlossarek
et al., 2012a). For determination of the activity, 30μg of pro-
tein were diluted in incubation buffer (20mM HEPES, 0.5mM
EDTA, 5mM DTT, 0.1mg/ml ovalbumin) to a final volume of
50μl. Samples were pre-incubated in this buffer for 2 h at 4◦C.
Following pre-incubation, the synthetic fluorogenic substrate
Suc-LLVY-AMC (Merck Biosciences) was added to the samples
at a final concentration of 60μM. After incubation in the dark
for 1 h at 37◦C, the fluorescence of the released AMC reporter
was measured using the TECAN Safire2 microplate reader at an
excitation wavelength of 380 nm and an emission wavelength of
460 nm. Each sample was measured in triplicate. The mean of the
blank (incubation buffer only) was subtracted from the mean of
each sample triplicate.
WESTERN BLOT
Western blot was performed in ventricular cytosolic lysates as
described previously (Schlossarek et al., 2012b). Primary anti-
body was directed against the β5-subunit of the proteasome
(kindly given by X.J. Wang, University of South Dakota, 1:5000).
Secondary antibody was anti-rabbit (Sigma, 1:6000, peroxidase-
conjugated). Signals were revealed with SuperSignal® West Dura
extended duration substrate (Pierce) and acquired with the
Chemie Genius2 Bio Imaging System.
ANALYSIS OF VENTRICULAR mRNAs
Total RNAwas extracted frommouse ventricles using the SV Total
RNA Isolation Kit (Promega) according to the manufacturer’s
instructions. RT-qPCR was performed as described previously
(Schlossarek et al., 2012b). The primers used to amplify the
β5-subunit of the proteasome (Psmb5), atrial natriuretic peptide
(Nppa), α-skeletal actin (Acta1), and guanine nucleotide binding
protein, alpha stimulating (Gnas) are listed in Table 1. Gnas was
used as an endogenous control to normalize the quantification
of the target mRNAs for difference in the amount of total RNA
added to each reaction.
Table 1 | PCR primer names and sequences.
Gene Target name Sequence
name
Psmb5 F Proteasome subunit, β5 5′-GAGCTTCGCAATAAGGAACG-3′
Psmb5 R Proteasome subunit, β5 5′-CTGTTCCCCTCGCTGTCTAC-3′
Nppa F Atrial natriuretic peptide 5′-ATCTGCCCTCTTGAAAAGCA-3′
Nppa R Atrial natriuretic peptide 5′-ACACACCACAAGGGCTTAGG-3′
Acta1 F α-skeletal actin 5′-CCCCTGAGGAGCACCCGACT-3′
Acta1 R α-skeletal actin 5′-CGTTGTGGGTGACACCGTCCC-3′








Abbreviations used are: F, forward primer; R, reverse primer.
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TRANSCRIPTOME ANALYSIS
Neonatal mouse cardiac myocytes were isolated from 0 to 4
day-old KI and WT pups and cultured as described previ-
ously (Vignier et al., 2009). After 3 days of plating cardiac
myocytes were either kept untreated or treated with 1μM
MG132 (Calbiochem) for 24 h. Total RNA was then extracted
from cultured cardiac myocytes using RNAzol® (WAK-Chemie),
according to the manufacturers’ instructions. RNA concentra-
tion, purity and quality were analyzed using the NanoDrop®
ND-1000 spectrophotometer (Thermo Scientific). Transcriptome
analysis of all samples was performed in triplicate using
Illumina Beadchips (Mouse WG-6 v2.0). The wet lab meth-
ods included amplification and fragmentation of the samples,
sample hybridization to the beadchip, and washing, staining
and scanning of the beadchip. For analysis, the Illumina Mouse
WG-6 v2.0 array data were quantile normalized on probe level
(45,281 probes) without background correction using Illumina
GenomeStudio V2011.1. Data of the 12 samples (four condi-
tions, three biological replicates) have been log2-transformed
after an offset addition (16). Probes fail to underrun a detection
p-value of 0.05 in any sample have been discarded before test
statistic (25,080 probes left). Probes and samples were analyzed
on significant expression differences according to the genotype
(KI or WT) and treatment (MG132-treated or untreated) using
Two-Way ANOVA statistic followed by FDR multiple testing cor-
rections (Benjamini and Hochberg, 1995). To avoid batch effects,
the Illumina slide was used as a cofactor in the test statistic.
Probes which undergo 5% FDR were selected as differentially
expressed. Probes, significant and more than four-fold regulated
between any of the four conditions, were clustered and heatmap
visualized. We performed hierarchical Euclidean average linkage
clustering for initial expression profile visualization (Figure 5)
using the pheatmap R package. Protein interaction of genes reg-
ulated by MG132-treatment have been further investigated by
using the String platform (Snel et al., 2000) and a high confidence
score (0.7).
STATISTICAL ANALYSIS
Data were expressed as mean ± s.e.m. Statistical analyses were
performed by Two-Way ANOVA followed by Bonferroni’s post-
test, or by paired or unpaired Student’s t-test as indicated in the
figure legends. All analyses were realized using the commercial
software GraphPad Prism5 (Software Inc.). A value of P < 0.05
was considered statistically significant. For transcriptomic analy-
sis, statistics are explained in the corresponding paragraph above.
RESULTS
REDUCTION OF CHYMOTRYPSIN-LIKE ACTIVITY BY 50%WITH
EPOXOMICIN
Seven week-old KI mice presented a 39% higher left ventric-
ular mass-to-body-weight (LVM/BW) ratio and a 29% lower
fractional area shortening (FAS) than age-matched WT mice
(Figure 1). We previously reported higher proteasome activi-
ties in 7-week-old KI than WT mice (Schlossarek et al., 2012a).
Sex-matched KI and WT mice were treated for 1 week with
epoxomicin (0.5mg/kg/day) or vehicle (NaCl in 10% DMSO)
according to Hedhli et al. (2008). Epoxomicin is a specific
FIGURE 1 | Echocardiographic analysis in KI vs. WT mice under basal
conditions. Echocardiographic analyses were performed in KI (gray) and
WT (white) mice under basal conditions, i.e., before minipump
implantation. (A) Left ventricular mass-to-body-weight ratio (LVM/BW). (B)
Fractional area shortening (FAS). Data are expressed as mean ± s.e.m. with
###P < 0.001 vs. WT, unpaired Student’s t-test. The number of animals is
indicated in the bars.
irreversible inhibitor of the β5-subunit of the proteasome and
responsible for the chymotrypsin-like activity (Hedhli and Depre,
2010). The chymotrypsin-like activity in cytosolic protein lysates
was ∼50% lower in KI and WT mice treated with epox-
omicin than in NaCl-treated mice (Figure 2A). Inhibition of
the β5-subunit did not come along with changes in the Psmb5
transcript level (Figure 2B), but with the appearance of two β5-
subunit bands in Western blot (Figure 2C). This was already
previously observed (Vignier et al., 2009) and likely represents
the free (lower band) and the epoxomicin-bound (upper band)
β5-subunit.
NO REGRESSION OF LEFT VENTRICULAR HYPERTROPHY BY
PROTEASOME INHIBITION
To determine whether proteasome inhibition had an effect on
LVH, echocardiography was performed after 1 week of treat-
ment. As expected, administration of NaCl did not alter the
LVM/BW ratio in both WT and KI mice (Figure 3A, left panel).
Likewise, the LVM/BW ratio did not differ before and after epox-
omicin treatment in both groups (Figure 3A, middle panel).
Finally, no difference in LVM/BW ratio was observed when
comparing the data only after treatment in both WT and
KI mice (Figure 3A, right panel). The heart-weight-to-body-
weight (HW/BW) and heart-weight-to-tibia-length (HW/TL)
ratios were 41% and 28% higher in NaCl-treated KI than WT
mice, respectively. Epoxomicin treatment did not affect both
ratios in both genotypes (Figure 3B). Finally, the transcript level
of two classical hypertrophy markers Nppa and Acta1 were higher
in NaCl-treated KI than WT mice and were not affected by
epoxomicin treatment (Figure 3C).
SLIGHT IMPROVEMENT OF CARDIAC FUNCTION BY PROTEASOME
INHIBITION
Cardiac function was examined by echocardiography after 1 week
of treatment. FAS was not affected in WT mice, whereas it was
reduced by 19% in KI mice by NaCl treatment (Figure 4A).
Conversely, FAS was increased by 15% in WT, but not affected
in KI mice by epoxomicin treatment (Figure 4B). However, when
we compared the data after treatment, FAS was 35% higher
after epoxomicin than after NaCl administration in KI mice
(Figure 4C). Although the FAS did not reach the level found in
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FIGURE 2 | Evaluation of chymotrypsin-like activity and β5-subunit
after proteasome inhibition in KI vs. WT mice. Analyses were performed
in KI (gray) and WT (white) mice treated for 1 week with epoxomicin (Epox;
stripes) or sodium chloride (NaCl; dots) via osmotic minipumps. (A)
Chymotrypsin-like activity in ventricular cytosolic protein extracts. (B)
β5-subunit mRNA level determined by RT-qPCR with SYBR Green and
normalized to Gnas. (C) Representative Western blot stained with an
anti-β5-subunit antibody. Data are expressed as mean ± s.e.m. with
∗∗∗P < 0.001 vs. corresponding NaCl-treated group, unpaired Student’s
t-test. The number of animals is indicated in the bars.
WTmice, these data suggest that epoxomicin partially rescued the
cardiac function in KI mice.
MARKED AND SIGNIFICANT DIFFERENTIAL GENE EXPRESSION IN
CARDIAC MYOCYTES AFTER PROTEASOME INHIBITION
To assess whether specific genes or biological pathways could
be involved in the improved cardiac function, we performed a
transcriptome analysis in WT and KI neonatal cardiac myocytes,
treated or not with 1μM of the reversible proteasome inhibitor
MG132 for 24 h. Gene expression profiles were then evalu-
ated by the Illumina Beadchips. ANOVA analysis over 25,080
expressed of 45,281 total probes led to a set of 4639 differen-
tial expressed probes (5% FDR) in strain (KI vs. WT; N = 37)
or treatment (untreated vs. MG132-treated; N = 4633). No sig-
nificant strain × treatment interaction was found. According to
the pronounced treatment effects we further focused onmarkedly
regulated probes (5% FDR in strain or treatment and a four-
fold regulation between any pair of conditions). Hierarchical
clustering of the resulting set of 404 probes (representing 339
genes) confirmed the dominance of MG132 treatment effects
(Figure 5A). A total of 197 genes (141 down and 56 up) and 161
genes (113 down and 48 up) were regulated by MG132 treatment
(four-fold, 5% FDR) in WT and KI cardiac myocytes, respec-
tively. Out of them, 103 genes were commonly regulated in both
groups (68 down and 35 up). Figures 5B,C show the string net-
work of interaction of most of the genes commonly ≥four-fold
down- or up-regulated in both KI and WT. Markedly down-
regulated genes encode for example proteins involved in the UPS
[such as ankyrin repeat and SOCS box containing 2 (ASB2) or
tripartite motif-containing 72 (TRIM72)], myofilament function
[such as α-myosin-heavy chain (MYH6) or cardiac troponin I
(TNNI3)], or calcium handling (such as phospholamban, PLN).
Markedly up-regulated genes encode for example transcription
factors [such as paired box 2 (PAX2) or DNA-damage-inducible
transcript 3 (DD1T3)], or molecular chaperones [such as heat
shock protein 90 kDa alpha (HSP90AA1), heat shock 70 kDa
protein 1a (HSPA1A) or F-box protein 2 (FBXO2) involved in
protein refolding]. Details for the 404 markedly and significantly
regulated probes are in the Supplemental Table 1.
DISCUSSION
In the present study we evaluated the cardiac phenotype after
1 week of proteasome inhibition in adolescent homozygous
Mybpc3-targeted KI and corresponding WT mice. At the inves-
tigated age of 7 weeks, KI mice exhibited a manifest LVH and car-
diac dysfunction. Based on previous publications (Hedhli et al.,
2008; Stansfield et al., 2008), we hypothesized that inhibition of
the UPS may be able to reduce preexisting LVH and improve car-
diac function in KI mice. The major findings of the present study
are: (1) no regression of preexisting hypertrophy in KI mice, (2)
slight improvement of cardiac function in WT mice, and (3) a
partial, but significant improvement of cardiac function in KI
mice by epoxomicin treatment. Finally, MG132 treatment of car-
diac myocytes revealed 103 genes which are commonly regulated
in KI and WT.
Elevated or impaired UPS function has been regularly reported
in experimental models of HCM and heart failure (Depre et al.,
2006; Tsukamoto et al., 2006; Schlossarek et al., 2012a), suggesting
that the regulation of the UPS belongs to important adaptations
in cardiac disease. In this context, proteasome inhibitors have
been suggested to be associated with anti-hypertrophic effects and
improved cardiac function. However, the in vivo effect of pro-
teasome inhibition was so far only investigated in animal models
with cardiac hypertrophy induced by isoprenaline, high salt diet
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FIGURE 3 | Evaluation of cardiac hypertrophy after proteasome inhibition
in KI vs. WTmice. Analyses were performed in KI (gray) andWT (white) mice
under basal conditions (basal; plain) or after 1 week of treatment with
epoxomicin (Epox; stripes) or sodium chloride (NaCl; dots) via osmotic
minipumps. (A) Left ventricular mass-to-body-weight ratio (LVM/BW)
determined by echocardiography. (B) Heart-weight-to-body-weight ratio
(HW/BW) and heart-weight-to-tibia-length ratio (HW/TL). (C) mRNA levels of
hypertrophymarkers determined by RT-qPCRwith SYBRGreen and normalized
to Gnas. Data are expressed as mean ± s.e.m. with ∗∗P < 0.01 and
∗∗∗P < 0.001 vs. WT in the same condition, Two-Way ANOVA plus Bonferroni’s
post-test. The number of animals is indicated in the bars. Abbreviations: Acta1,
α-skeletal actin; Nppa, atrial natriuretic peptide.
FIGURE 4 | Evaluation of cardiac function after proteasome inhibition in
KI vs. WT mice. Fractional area shortening (FAS) was determined by
echocardiography in KI (gray) and WT (white) mice under basal conditions
(basal; plain; A, B) or after 1 week of treatment with epoxomicin (Epox;
stripes; B, C) or sodium chloride (NaCl; dots; A, C) via osmotic minipumps.
Data are expressed as mean ± s.e.m. with ∗∗P < 0.01 and ∗∗∗P < 0.001 vs.
WT in the same condition, Two-Way ANOVA plus Bonferroni’s
post-test, #P < 0.05 vs. corresponding basal, paired Student‘s t-test, and
§P < 0.05 vs. KI NaCl, unpaired Student‘s t-test. The number of animals is
indicated in the bars.
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FIGURE 5 | Transcriptome analysis. Cardiac myocytes were isolated from
neonatal KI and WT mice and treated with the proteasome inhibitor
MG132 (1μM) or left untreated for 24 h. RNAs were subjected to
transcriptome analysis using the Illumina Beadchips. (A) Clustering of the
four-fold and significantly (5% FDR) regulated expressed probes
(N = 404). The heatmap and the dendrograms representing the results of
the hierarchical clustering of standardized log2 signal values. (B), (C)
String networks of four-fold and significant differentially expressed (5%
FDR) genes commonly regulated in KI and WT cardiac myocytes
[N = 103, 68 down (B) and 35 up (C)]. Known and predicted protein
interactions including direct (physical) and indirect (functional) associations
are visualized in a network. The size of the connecting lines represents
the impact of the connection. Only high confidence String interactions
are shown.
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or TAC, but not in genetically-modified HCMmouse models as it
is the case in the present study. In contrast to the previous studies,
we did not observe a regression of preexisting cardiac hypertro-
phy after proteasome inhibition in KI mice. Neither LVM/BW
nor HW/BW or HW/TL changed after 1 week of treatment with
epoxomicin. Furthermore, mRNA levels of hypertrophy mark-
ers did not decrease after treatment. The discrepancy between
previous and present findings may be explained by the manifes-
tation of cardiac hypertrophy in the investigated models. In the
previous studies cardiac hypertrophy was achieved in mice by
2-week of either TAC (Hedhli et al., 2008) or isoprenaline infu-
sion (Stansfield et al., 2008). In contrast, the KI mice already
develop LVH at postnatal day 3 (Gedicke-Hornung et al., 2013)
and proteasome inhibition was performed at the age of 7 weeks.
Therefore, cardiac hypertrophy was present for a longer time
period than in previous studies and could be associated withmore
remodeling of the cardiac tissue.
Analysis of the cardiac function, on the other hand, displayed
already challenging findings after 1 week of treatment. First, and
unexpectedly, KI, but not WT mice exhibited a slight, but signifi-
cant decrease in cardiac function after 1 week of NaCl administra-
tion (Figure 4A). The reason is not certain but it could be related
to the combination of stress due to minipump implantation plus
mutation in KI mice. This is in agreement with our previous data
obtained in heterozygous KI mice (Schlossarek et al., 2012b). The
stress induced by minipump implantation does not affect the WT
mice, likely because they do not have a disease phenotype. Second,
epoxomicin treatment improved cardiac function in WT, but not
at first glance in KI mice (Figure 4B). Since the WT mice are able
to cope with the stress, we directly see the effect of epoxomicin.
On the contrary, since the KI mice are not able to cope with the
stress (negative effect on FAS), the positive effect of epoxomicin
cannot be seen directly (=no change in FAS). However, directly
comparing the effects of epoxomicin and NaCl after 1 week of
treatment suggests that epoxomicin indeed had a positive effect
also in KI mice (Figure 4C).
To identify which genes or pathways could be involved in
this positive effect, transcriptome analysis was performed in KI
and WT neonatal cardiac myocytes, treated or not with the pro-
teasome inhibitor MG132. This revealed marked and significant
differentially expressed genes. Focus on the commonly regulated
genes in MG132-treated KI and WT cardiac myocytes revealed
up-regulation of genes encoding transcription factors or pro-
teins involved in protein re-folding, as well as down-regulation
of genes encoding proteins involved in the UPS or calcium han-
dling. The latter for example includes PLN, which is an inhibitor
of the sarcoplasmic reticulum calcium-ATPase, and therefore its
down-regulation could contribute to the better cardiac function
observed upon epoxomicin treatment in vivo.
Since the UPS plays a role in many fundamental biologi-
cal processes, targeting this system for therapy is complex and
particularly some conflicting data exist that argue against the
anti-hypertrophic and function-stabilizing effects of proteasome
inhibitors in chronic application (Herrmann et al., 2013). In
addition, while bortezomib (reversible proteasome inhibitor) is
generally well tolerated by patients with multiple myeloma, it has
been shown to increase the occurrence of cardiac complications
ranging from arrhythmia to congestive heart failure in elderly
patients or patients with preexisting cardiac problems (Enrico
et al., 2007; Hacihanefioglu et al., 2008; Bockorny et al., 2012).
In conclusion, whereas chronic proteasome inhibition may
give additional stress to the heart and promote transition to heart
failure, our data revealed that partial and short-term proteasome
inhibition does not suppress LVH but slightly improved cardiac
function in a mouse model of HCM. Targeting the UPS acutely
therefore remains a therapeutic option for cardiac diseases with
reduced cardiac function.
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